Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Response to Letter]
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J
. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741):595-605.
DOI: 10.1016/S0140-6736(10)60888-4.
View
2.
Hollander P, Gupta A, Plodkowski R, Greenway F, Bays H, Burns C
. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013; 36(12):4022-9.
PMC: 3836105.
DOI: 10.2337/dc13-0234.
View
3.
Apovian C, Aronne L, Rubino D, Still C, Wyatt H, Burns C
. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013; 21(5):935-43.
PMC: 3739931.
DOI: 10.1002/oby.20309.
View
4.
Wu L, Hu J, Yao P
. Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Letter]. Drug Des Devel Ther. 2024; 18():5793-5794.
PMC: 11633288.
DOI: 10.2147/DDDT.S509093.
View
5.
Wadden T, Foreyt J, Foster G, Hill J, Klein S, ONeil P
. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2010; 19(1):110-20.
PMC: 4459776.
DOI: 10.1038/oby.2010.147.
View